Drug Trial Radar · NCT07072468
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Dec 12, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- VM Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes, and vinca alkaloids, which can damage nerve fibres by disrupting their structure and function. At present, relief of neuropathic pain in CIPN is limited, and existing therapies providing only modest and variable efficacy across patients. This is a study of VMD-3866 gel (the study medicine which is non-opioid, non-NSAID), an experimental new topical medicine for treating pain caused by CIPN. The goal of this study is to assess if the study medicine improves pain symptoms in patients with CIPN, and to find out the side effects of the study medicine if any. The study medicine will work by selectively blocking a specific sub-type of proteins (called T-type calcium channels) in the nerves under the skin which will lower the activity of the nerves and therefore reduce pain. It is a topical gel, meaning that it is applied to the skin, and its novel gel formulation limits that only little amount of study medicine may enter the blood and none enters the brain. This means it's unlikely to be addictive and it's unlikely to have any impact on participant current medications. Researchers will compare study medicine to a matching placebo (a look-alike gel that contains no drug) to see if VMD-3866 gel works to management of pain caused by CIPN.
Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Chemotherapy-induced Neuropathic Pain
- CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Peripheral Neuropathic Pain
- Peripheral Nerve Injuries
- Pain, Nerve
- Pain, Chronic
- Pain, Neuropathic
- Peripheral Nerve Injury Lower Leg
- Peripheral Nerve Injury at Ankle and Foot Level (Diagnosis)
- Peripheral Nerve Injury Digital Nerve Foot (Diagnosis)
- Peripheral Nerve Injury at Ankle and Foot Level
- Peripheral Nerve Injury at Lower Leg Level (Diagnosis)
- Pain Management
- Toxic Neuropathy
- Painful Paresthesia
- Dysesthesia
Interventions
VMD-3866 GelDrug
Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose). Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home.
Placebo GelDrug
Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose). Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the sum of daily numeric pain rating scale (NPRS) score at the end of each treatment period.Time frame: Daily for 8 days for each of 2 treatment periods, up to 1 month in total
- Number of participants with an Adverse Event (AE).Time frame: Daily for 8 days for each of 2 treatment periods, up to 1 month in total
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research Ltd (24-503; Tel: 0800 783 8792; recruit@hmrlondon.com)
London, UK, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.